(Q37913528)

25 August 2017

1 reference

title

The future of incretin-based therapy: novel avenues--novel targets (English)

1 reference

25 August 2017

B Ahrén

1

1 reference

25 August 2017

language of work or name

1 reference

1 October 2011

1 reference

Diabetes, Obesity and Metabolism

25 August 2017

published in

1 reference

25 August 2017

volume

13 Suppl 1

1 reference

25 August 2017

page(s)

158-166

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

The role of GLP-1 in the life and death of pancreatic beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

GLP-1 for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

A review of exenatide as adjunctive therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Liraglutide: the therapeutic promise from animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Efficacy and safety of incretin based therapies: clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Islet transplantation for brittle type 1 diabetes: the UIC protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Glucagon-Like Peptide 1—A Cardiologic Dimension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Incretin hormone secretion over the day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Molecular mechanisms underlying nutrient-stimulated incretin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Lipid receptors and islet function: therapeutic implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Treatment of diabetes with glucagon-like peptide-1 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Therapeutic potential for GIP receptor agonists and antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Suppression of weight gain by glucagon in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Peptide YY, appetite and food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Peptide YY does not inhibit glucose-stimulated insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Gut hormones: implications for the treatment of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Ghrelin in the regulation of body weight and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

1,5-Anhydro-d-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01457.X

10.1111/J.1463-1326.2011.01457.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference